|
Saudi Arabia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Saudi Arabia Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Saudi Arabia .
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Saudi pharmaceutical and healthcare industry.
Competitive intelligence, Saudi pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Saudi market.
The Saudi Arabia Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Saudi Arabia Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Saudi pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Saudi Arabia to test other views – a key input for successful budgeting and strategic business planning in the Saudi pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Saudi Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Saudi Arabia .
- Exploit The Latest Competitive Saudi Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Saudi Arabia .
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Saudi Arabia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| SWOT Analysis |
| Saudi Arabia Political SWOT |
| Saudi Arabia Economic SWOT |
| Saudi Arabia Business Environment SWOT |
| Table: Saudi Arabia Pharmaceuticals And Healthcare SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Middle East And Africa Pharmaceutical Business Environment Ratings |
| Limits of Potential Returns |
| Risks to Realisation of Returns |
Chapter - Saudi Arabia – Market Summary |
| Regulatory Regime |
| Regional Regulatory Developments |
| Free Trade Agreements |
| Intellectual Property Developments |
| IP Deficiencies |
| Pricing and Reimbursement Issues |
| Tendering Procedures |
Chapter - Industry Developments |
| Epidemiology |
| HIV/AIDS |
| Healthcare Sector |
| Primary Healthcare Provision |
| Secondary Healthcare Provision |
| Recent Healthcare Provision Developments |
| Health Insurance |
| Pharmaceutical Sector |
| Pharmaceutical Distribution Sector |
| Table: Saudi Arabian Drug Distribution Firms |
| Recent Pharmaceutical Company Activities |
| Medical Device Sector |
| Research and Development |
Chapter - Industry Forecast Scenario |
| Key Growth Factors – Industry |
| Table: Saudi Arabian Health Expenditure Indicators, 2004-2013 |
| Overall Market Forecasts |
| Table: Saudi Arabia's Drug Market Indicators, 2004-2013 (US$mn unless otherwise stated) |
| Macroeconomic Scenario |
| Table: Saudi Arabia – Economic Activity |
| Patented Drug Market Forecast |
| Table: Saudi Arabia - Patented Drug Market 2004-2013 |
| Generic Drug Market Forecast |
| Table: Saudi Arabia's Generic Drug Market, 2004-2013 |
| OTC Drug Market Forecast |
| Table: Saudi Arabia OTC Drug Market, 2004-2013 (US$mn unless otherwise stated) |
| Medical Device Market Forecast |
| Table: Saudi Arabia's Medical Device Market, 2004-2013 (US$mn unless otherwise stated) |
| Pharmaceutical Export/Import Market Forecasts |
| Table: Saudi Arabia's Pharmaceutical Export/Import Forecast (US$mn) 2004-2013 |
| Other Healthcare Data Forecasts |
| Table: Saudi Arabia's Other Healthcare Data And Forecasts 2004-2013 |
| Key Risks to BMI Forecasts |
Chapter - Competitive Landscape |
| Company Profiles |
| Multinational Company Profiles |
| GlaxoSmithKline |
| Novartis |
| Merck & Co |
| Pfizer |
| Sanofi-Aventis |
| Indigenous Company Profiles |
| Saudi Pharmaceutical Industries & Medical Appliances Corp (SPIMACO) |
| Saudi Arabian Japanese Pharmaceutical (SAJA) |
| TABUK Pharmaceutical Manufacturing |
| Al Jazeera Pharmaceutical Industries (JPI) |
Chapter - Country Snapshot: Saudi Arabia Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education and Healthcare |
| Table: Education, 2003-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market and Spending Power |
| Table: Employment Indicators, 1999-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Saudi Arabia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
BMI forecasts that total pharmaceutical spending in Saudi Arabia will increase from US$2.65bn in 2008 to US$3.68bn by 2013, representing a compound annual growth rate of 6.8% in US dollar terms. We believe that the main drivers for growth will be the increasing burden of respiratory diseases in the country, coupled with the rise of obesity-related disorders, including diabetes and hypertension. Expenditure is also expected to rise in line with planned healthcare reforms to introduce mandatory health insurance throughout the Kingdom. With respect to this, we also foresee the Ministry of Health beginning to manoeuvre itself into a more regulatory role within the scope of the new reforms. While the government wishes to reduce its public sector healthcare spending, it also plans to radically improve the quality and standard of care at Saudi hospitals.
According to BMI's Burden of Disease Database (BoDD), the number of disability-adjusted life years (DALYs) lost to lower respiratory tract infections will decrease from 135,806 in 2008 to 61,352 by 2030, representing a decline of 55%. The proportion of this burden on the total number of DALYs in the Kingdom will fall from 4.3% to 1.6% over the same period. While this is encouraging, we note that the rise in antibiotic resistance in the Kingdom will need to be addressed by the Ministry of Health in order to support a continuation of this trend.
The Kingdom’s plan to provide medical insurance to 1.5mn Saudi employees by Q309 is expected to increase the value of the total insurance market in the country by US$534mn. Collaborative plans were drafted during December 2008 between health insurance firms and governmental bodies, including the Ministry of Labour. BMI cautions that, though extended coverage will increase overall healthcare spending, it is likely that premiums will increase with more comprehensive coverage to cope with rising demand. Additionally, we warn that more time may be needed in order for insurance firms to cope with the rapid rise in uptake, which may delay the target for mandatory coverage in the private sector until early 2010.
In 2008, the value of the medical insurance sector was US$700mn. During 2006-2008 this sector experienced strong growth to achieve just under a third of the total insurance market. In BMI's view, gradually increasing coverage and ensuring that policies are transparent will allow this growth trend to continue in order to meet the government's targets.
|
Saudi Arabia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |